To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder

NCT ID: NCT04440696

Last Updated: 2021-07-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-21
• Study Completion Date: 2022-12-31

Brief Summary

The aim of the study is:

To evaluate the tolerance of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia with multiple doses and multiple doses； To evaluate the pharmacodynamics of lanthanum polystyrene sulfonate powder in hyperphosphatemia patients with end-stage renal disease on hemodialysis (ESRD-HD); To evaluate the pharmacokinetics of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia after multi-dose and multiple administration.

Conditions

Hyperphosphatemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

group 1:dose 1.5g

There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）

Group Type: EXPERIMENTAL

Lanthanum Polystyrene Sulphonate Powder

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Lanthanum Carbonate 500 MG

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Placebo

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

group 2:dose 3g

There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）

Group Type: EXPERIMENTAL

Lanthanum Polystyrene Sulphonate Powder

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Lanthanum Carbonate 500 MG

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Placebo

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

group 3:dose 4.5g

There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）

Group Type: EXPERIMENTAL

Lanthanum Polystyrene Sulphonate Powder

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Lanthanum Carbonate 500 MG

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Placebo

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

group 4:dose 6g

There were 12 subjects in the group, 8 of whom took lanthanum polystyrene sulfonate powder, 2 took placebo, and 2 took positive control drug （lanthanum carbonate）

Group Type: EXPERIMENTAL

Lanthanum Polystyrene Sulphonate Powder

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Lanthanum Carbonate 500 MG

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Placebo

Intervention Type: DRUG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Interventions

Lanthanum Polystyrene Sulphonate Powder

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention Type: DRUG

Lanthanum Carbonate 500 MG

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention Type: DRUG

Placebo

D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1) Sign the informed consent before the trial, and fully understand the test content, process and possible adverse reactions;
• 2) Able to complete the study according to the requirements of the experimental program, able to accept dietary management and unified diet during the trial;
• 3) Regular hemodialysis was performed three times a week in the 12 weeks before screening (the total number of weeks without three times a week for special reasons should not exceed 2 weeks), and the dialysis regimen was expected to remain unchanged during the trial;
• 4) The patient is receiving appropriate dialysis treatment, and the urea clearance index (KT /V) ≥1.2 (the KT /V value of the research center within one month before screening is valid, and the results of several measurements shall be subject to the latest measurement);
• 5) Subjects (including partners) are willing to voluntarily use effective contraceptive measures within 6 months from the screening to the last study drug administration, as detailed contraceptive measures are shown in Appendix 4;
• 6) Male and female subjects aged 18 to 65 years (including 18 and 65 years) with a body mass index (BMI) in the range of 18 to 35 kg/m2 (including the threshold);
• 7) In patients with end-stage renal disease hyperphosphatemia, fasting blood phosphorus ≥1.78mmol/L and ≤3.23mmol/L were measured at screening and admission.

Exclusion Criteria

• 1) A history of clinically significant drug allergy or atopic allergic disease (asthma, urticaria, eczema dermatitis) or known allergy to the experimental drug or similar drug;
• 2) Patients who had severe trauma or had undergone major surgery within 6 months prior to the trial, or who planned to undergo surgery during the study period were screened;
• 3) Blood loss > 450mL in the three months before screening;
• 4) Clinical, radiological or laboratory evidence of active tuberculosis (TB);
• 5) Previous kidney transplantation operations;
• 6) A history of drug use and/or alcohol abuse in the 3 months prior to screening (14 units of alcohol consumed per week: 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine);
• 7) Those who were receiving any vitamin D or calcium-like regimens at the time of screening and could not maintain a stable dose after admission (except those who were receiving a stable vitamin D or calcium-like regimens);
• 8) Have dysphagia or gastrointestinal history with any influence on drug absorption, including but not limited to intestinal obstruction, macrocolon, habitual constipation (stool frequency < 1 times per week), chronic diarrhea (stool frequency ≥4 times per day), gastroparesis with nausea or vomiting and other gastrointestinal disorders and gastrointestinal surgery;
• 9) suffer from any disease that increases the risk of gastrointestinal bleeding, such as acute erosive gastritis, acute hemorrhagic necrotizing enteritis, or active gastrointestinal ulcer;
• 10) For poorly controlled hypertension, the systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg should be measured at rest, and the patient should be rechecked at most twice for confirmation;
• 11) The history of acute coronary syndrome (such as myocardial infarction, unstable angina pectoris hospitalization), or percutaneous coronary intervention, or coronary artery bypass grafting in the previous 12 months was screened;Or had an arterial/venous thrombosis event, such as a cerebrovascular accident (including a history of stroke or transient ischemic attack), deep venous thrombosis and pulmonary embolism, within 12 months before screening;
• 12) Uncontrolled severe arrhythmias, such as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia, that were not controlled by medication or other treatment in the 12 months prior to enrolment;
• 13) Unstable and serious diseases of the digestive system, respiratory system, mental nervous system, endocrine system, blood system, malignant tumor, etc., which are not suitable for the study as judged by the study doctor;
• 14) Screening patients with a history of acute or severe infection within the previous 1 month;
• 15) Take phosphorus-reducing drugs, such as lanthanum carbonate, calcium carbonate, calcium acetate, aluminum hydroxide, Sveram, etc., within 14 days before administration;Drugs that may affect lanthanum ion release, such as proton pump inhibitors, H2 receptor antagonists, etc.And drugs that interact with experimental drugs, such as ciprofloxacin hydrochloride, thyroxine, lithium, etc.;Drugs containing phosphoric acid components, such as oseltamivir phosphate, sitagliptin phosphate tablets, etc.
• 16) Those who have participated in any clinical trials of drugs or medical devices within one month before taking the study drug;
• 17) During screening, hemoglobin ≤90g/L and albumin ≤30g/L;
• 18) Hypercalcemia, blood calcium ≥2.52mmol/L;Hypocalcemia, blood calcium ≤1.80mmol/L (corrected blood calcium value: corrected blood calcium value mmol/L= measured calcium value mmol/L+0.02× (40g/L- measured serum albumin value g/L));
• 19) Severe hyperparathyroidism, parathyroid hormone (PTH) >1200pg/mL;
• 20) Female subjects with positive blood pregnancy results during the screening period or baseline period;
• 21) HIV antigen/antibody positive;Positive antibody to Treponema pallidum and positive serological test of non-Treponema pallidum (such as rapid plasma reaction test, toluidine red unheated serum test, etc.);
• 22) A history of heart failure as defined by the New York College of Cardiology (NYHA) as III-IV, or a left ventricular ejection fraction less than 40%;
• 23) Subjects who have other factors considered by the investigator to be unsuitable for participating in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Hospital of Jilin University

OTHER

Sponsor Role: collaborator

Grand Life Science (Liaoning) Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yanhua Ding, Ph.D

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Jilin University

Locations

The First Hospital of Jilin University

Changchun, Jilin, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiaoyan Wen, MA

Role: CONTACT

wenxiaoyan@nkbp.com

+86 18704019565

Facility Contacts

Yanhua Ding

Role: primary

dingyanhua2003@126.com

18186879468

Other Identifiers

JBL-2019-001

Identifier Type: -

Identifier Source: org_study_id